Sergio Traversa - Jun 30, 2022 Form 4 Insider Report for RELMADA THERAPEUTICS, INC. (RLMD)

Role
Chief Executive Officer, Director
Signature
/s/ Sergio Traversa
Stock symbol
RLMD
Transactions as of
Jun 30, 2022
Transactions value $
-$83,305
Form type
4
Date filed
7/5/2022, 04:30 PM
Previous filing
May 26, 2022
Next filing
Dec 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLMD Common Stock Options Exercise $256K +16K +18.04% $16.00* 105K Jun 30, 2022 Direct F1
transaction RLMD Common Stock Sale -$103K -5.31K -5.07% $19.37* 99.5K Jun 30, 2022 Direct F2, F3
transaction RLMD Common Stock Sale -$203K -10.7K -10.75% $19.01* 88.8K Jun 30, 2022 Direct F2, F4
transaction RLMD Common Stock Options Exercise $220K +13.8K +15.49% $16.00* 103K Jul 1, 2022 Direct F1
transaction RLMD Common Stock Sale -$15.5K -839 -0.82% $18.48* 102K Jul 1, 2022 Direct F2, F5
transaction RLMD Common Stock Sale -$163K -8.85K -8.7% $18.45* 92.8K Jul 1, 2022 Direct F2, F6
transaction RLMD Common Stock Sale -$74.5K -4.07K -4.38% $18.32* 88.8K Jul 1, 2022 Direct F2, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RLMD Stock Option (right to buy) Options Exercise $0 -16K -53.79% $0.00 13.8K Jun 30, 2022 Common Stock 16K $16.00 Direct F1, F8
transaction RLMD Stock Option (right to buy) Options Exercise $0 -13.8K -100% $0.00* 0 Jul 1, 2022 Common Stock 13.8K $16.00 Direct F1, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction reported on this Form 4 reflects the exercise of stock options set to expire on July 10, 2022.
F2 The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.
F3 Sales prices range from $19.20 to $19.51 per share, inclusive.
F4 Sales prices range from $19.00 to $19.15 per share, inclusive.
F5 Sales prices range from $18.47 to $18.53 per share, inclusive.
F6 Sales prices range from $18.45 to $18.47 per share, inclusive.
F7 Sales prices range from $18.26 to $18.44 per share, inclusive.
F8 The options were granted on July 10, 2012 (the "Grant Date"). 25% of the options vested upon the Grant Date and the remaining 75% of the options vested in equal quarterly increments over the next four (4) years, so that the last set of options vested in July 2016.